FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis

Incyte announced that the FDA has accepted for filing the new drug application (NDA) for Incyte’s lead investigational compound, ruxolitinib, as a potential treatment for patients with myelofibrosis (MF).
MarketWatch